Literature DB >> 29802140

Notch inhibitor screening reveals an unexpected HES1 heterodimer.

Krizia Rohena-Rivera1, Neil A Bhowmick2.   

Abstract

Notch signaling plays critical roles in cancer progression, motivating efforts to identify inhibitors of this pathway. Perron et al. report a small-molecule screen intended to discover compounds that could interfere with the downstream transcription factor HES1. Target validation of their compounds unexpectedly identified a novel HES1-interacting protein, prohibitin 2. This highlights a new mechanism to block Notch signaling and prompting further exploration of HES1 biology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29802140      PMCID： PMC5971460          DOI： 10.1074/jbc.H118.002880

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Notch signaling: an emerging therapeutic target for cancer treatment.

Authors:  Xun Yuan; Hua Wu; Hanxiao Xu; Huihua Xiong; Qian Chu; Shiying Yu; Gen Sheng Wu; Kongming Wu
Journal:  Cancer Lett       Date:  2015-09-01       Impact factor: 8.679

Review 2.  Prohibitin 2: At a communications crossroads.

Authors:  Alberto Bavelloni; Manuela Piazzi; Mirco Raffini; Irene Faenza; William L Blalock
Journal:  IUBMB Life       Date:  2015-04-21       Impact factor: 3.885

3.  Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

Authors:  Wan-Ching Yen; Marcus M Fischer; Fumiko Axelrod; Christopher Bond; Jennifer Cain; Belinda Cancilla; William R Henner; Rene Meisner; Aaron Sato; Jalpa Shah; Tracy Tang; Breanna Wallace; Min Wang; Chun Zhang; Ann M Kapoun; John Lewicki; Austin Gurney; Timothy Hoey
Journal:  Clin Cancer Res       Date:  2015-05-01       Impact factor: 12.531

Review 4.  Hes1: a key role in stemness, metastasis and multidrug resistance.

Authors:  Zi-Hao Liu; Xiao-Meng Dai; Bin Du
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor.

Authors:  Yongjie Wei; Wei-Chung Chiang; Rhea Sumpter; Prashant Mishra; Beth Levine
Journal:  Cell       Date:  2016-12-22       Impact factor: 41.582

6.  Therapeutic targeting of HES1 transcriptional programs in T-ALL.

Authors:  Stephanie A Schnell; Alberto Ambesi-Impiombato; Marta Sanchez-Martin; Laura Belver; Luyao Xu; Yue Qin; Ryoichiro Kageyama; Adolfo A Ferrando
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

7.  Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone.

Authors:  Amelie Perron; Yoshihiro Nishikawa; Jun Iwata; Hiromi Shimojo; Junichiro Takaya; Kumiko Kobayashi; Itaru Imayoshi; Naasson M Mbenza; Mihoko Takenoya; Ryoichiro Kageyama; Yuzo Kodama; Motonari Uesugi
Journal:  J Biol Chem       Date:  2018-03-09       Impact factor: 5.157

8.  Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1.

Authors:  Kaoru Murata; Masakazu Hattori; Norihito Hirai; Yoriko Shinozuka; Hiromi Hirata; Ryoichiro Kageyama; Toshiyuki Sakai; Nagahiro Minato
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 9.  Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.

Authors:  Rajesh Kumar; Lucienne Juillerat-Jeanneret; Dela Golshayan
Journal:  J Med Chem       Date:  2016-04-18       Impact factor: 7.446

10.  Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors:  Marzia A Locatelli; Philippe Aftimos; E Claire Dees; Patricia M LoRusso; Mark D Pegram; Ahmad Awada; Bo Huang; Rossano Cesari; Yuqiu Jiang; M Naveed Shaik; Kenneth A Kern; Giuseppe Curigliano
Journal:  Oncotarget       Date:  2017-01-10
  10 in total
  1 in total

Review 1.  A Review on Notch Signaling and Colorectal Cancer.

Authors:  Ashish Tyagi; Arun K Sharma; Chendil Damodaran
Journal:  Cells       Date:  2020-06-25       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.